Oxidative stress in schizophrenia

Current Neuropharmacology

Volumn 9, Issue 2, 2011, Pages 301-312

  Bošković, Marija ^a   Vovk, Tomaž ^a   Plesničar, Blanka Kores ^b   Grabnar, Iztok ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY PSYCHIATRIC HOSPITAL   (Slovenia)

Author keywords

Antioxidants; Antipsychotics; Biochemical markers; Fatty acids; Oxidative stress; Schizophrenia; Tardive dyskinesia

Indexed keywords

4 HYDROXYNONENAL; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; AMINE OXIDASE (FLAVIN CONTAINING); ASCORBIC ACID; BETA CAROTENE; BIOLOGICAL MARKER; CATALASE; CLOZAPINE; DOCOSAHEXAENOIC ACID; DOPAMINE; FATTY ACID; GLUTATHIONE PEROXIDASE; HALOPERIDOL; HOMOCYSTEINE; HYDROGEN PEROXIDE; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; MALONALDEHYDE; NEUROTRANSMITTER; NITRIC OXIDE; NITRITE; OLANZAPINE; POLYUNSATURATED FATTY ACID; REACTIVE OXYGEN METABOLITE; RISPERIDONE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ZIPRASIDONE;

AIDS PATIENT; AMINO ACID COMPOSITION; ANTIOXIDANT ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; COCHRANE LIBRARY; CYTOTOXICITY; DNA DAMAGE; EMBASE; ERYTHROCYTE; EXTRAPYRAMIDAL SYMPTOM; GENE EXPRESSION; GINKGO BILOBA; HEART DISEASE; HEREDITY; HUMAN; INFORMATION RETRIEVAL; LIPID PEROXIDATION; MEDLINE; MITOCHONDRIAL ENERGY TRANSFER; MULTIPLE SCLEROSIS; NERVE CELL; NEUROLOGIC DISEASE; NEUTROPHIL; NUTRITIONAL INTOLERANCE; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PUBLICATION; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 79958169285     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015911795596595     Document Type: Article

References (153)

1. Schultz, S.H.; North, S.W.; Shields, C.G. Schizophrenia: a review. Am. Fam. Phys., 2007, 75(12), 1821-1829.
2. Nestler, E.; Hyman, S.; Malenka, R. Molecular neuropharmacology: A foundation of Clinical Neuroscience; McGraw-Hill companies: New York, 2001; pp. 383-407.
3. Mahadik, S.P.; Pillai, A.; Joshi, S.; Foster, A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int. Rev. Psychiatry, 2006, 18(2), 119-131.
4. Ranjekar, P.K.; Hinge, A.; Hegde, M.V.; Ghate, M.; Kale, A.; Sitasawad, S.; Wagh, U.V.; Debsikdar, V.B.; Mahadik, S.P. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res., 2003, 121(2), 109-122.
5. Ng, F.; Berk, M.; Dean, O.; Bush, A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol., 2008, 11(6), 851-876.
6. Halliwell, B.; Gutteridge, J.M.C. Free Radicals in Biology and Medicine; Oxford University Press: Oxford, 2007; pp. 440-613.
7. Mahadik, S.P.; Mukherjee, S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res., 1996, 19(1), 1-17.
8. Perez-Neri, I.; Ramirez-Bermudez, J.; Montes, S.; Rios, C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem. Res., 2006, 31(10), 1279-1294.
9. Fendri, C.; Mechri, A.; Khiari, G.; Othman, A.; Kerkeni, A.; Gaha, L. [Oxidative stress involvement in schizophrenia pathophysiology: a review]. Encephale., 2006, 32(2 Pt 1), 244-252.
10. Mukerjee, S.; Mahadik, S.P.; Scheffer, R.; Correnti, E.E.; Kelkar, H. Impaired antioxidant defense at the onset of psychosis. Schizophr. Res., 1996, 19(1), 19-26.
11. Mahadik, S.P.; Evans, D.; Lal, H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2001, 25(3), 463-493.
12. Michel, T.M.; Thome, J.; Martin, D.; Nara, K.; Zwerina, S.; Tatschner, T.; Weijers, H.G.; Koutsilieri, E. Cu, Zn-and Mn superoxide dismutase levels in brains of patients with schizophrenic psychosis. J. Neural. Transm., 2004, 111(9), 1191-1201.
13. Khan, M.M.; Evans, D.R.; Gunna, V.; Scheffer, R.E.; Parikh, V.V.; Mahadik, S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the nevermedicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res., 2002, 58(1), 1-10.
14. Halliwell, B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging, 2001, 18(9), 685-716.
15. Halliwell, B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem., 2006, 97(6), 1634-1658.
16. Uttara, B.; Singh, A.V.; Zamboni, P.; Mahajan, R.T. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol., 2009, 7(1), 65-74.
17. Halliwell, B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol., 2006, 141(2), 312-322.
18. Dorfman-Etrog, P.; Hermesh, H.; Prilipko, L.; Weizman, A.; Munitz, H. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study. Eur. Neuropsychopharmacol., 1999, 9(6), 475-477.
19. Gilgun-Sherki, Y.; Melamed, E.; Offen, D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology, 2001, 40(8), 959-975.
20. Harris, E.D. Regulation of antioxidant enzymes. FASEB J., 1992, 6(9), 2675-2683.
21. Akyol, O.; Herken, H.; Uz, E.; Fadillioglu, E.; Unal, S.; Sogut, S.; Ozyurt, H.; Savas, H.A. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2002, 26(5), 995-1005.
22. Yanik, M.; Vural, H.; Kocyigit, A.; Tutkun, H.; Zoroglu, S.S.; Herken, H.; Savas, H.A.; Koylu, A.; Akyol, O. Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia? Neuropsychobiology, 2003, 47(2), 61-65.
23. Do, K.; Bovet, P.; Cuenod, M. Schizophrenia: Glutathione deficit as a new vulnerability factor for disconectivity sindrome. Schweiz. Arch. Psyciatr., 2004, 155(8), 375-385.
24. Grima, G.; Benz, B.; Parpura, V.; Cuenod, M.; Do, K.Q. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr. Res., 2003, 62(3), 213-224.
25. Do, K.Q.; Trabesinger, A.H.; Kirsten-Kruger, M.; Lauer, C.J.; Dydak, U.; Hell, D.; Holsboer, F.; Boesiger, P.; Cuenod, M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci., 2000, 12(10), 3721-3728.
26. Dietrich-Muszalska, A.; Olas, B.; Rabe-Jablonska, J. Oxidative stress in blood platelets from schizophrenic patients. Platelets, 2005, 16(7), 386-391.
27. Berger, G.E.; Smesny, S.; Amminger, G.P. Bioactive lipids in schizophrenia. Int. Rev. Psychiatry, 2006, 18(2), 85-98.
28. Yao, J.K.; Leonard, S.; Reddy, R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res., 2000, 42(1), 7-17.
29. Yao, J.K.; van Kammen, D.P.; Gurklis, J. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophr. Res., 1994, 13(3), 227-232.
30. Williamson, P.C.; Brauer, M.; Leonard, S.; Thompson, T.; Drost, D. 31P magnetic resonance spectroscopy studies in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids, 1996, 55(1-2), 115-118.
31. Pearce, J.M.; Komoroski, R.A.; Mrak, R.E. Phospholipid composition of postmortem schizophrenic brain by 31P NMR spectroscopy. Magn. Reson. Med., 2009, 61(1), 28-34.
32. Terpstra, M.; Vaughan, T.J.; Ugurbil, K.; Lim, K.O.; Schulz, S.C.; Gruetter, R. Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia. Magma, 2005, 18(5), 276-282.
33. Wood, S.J.; Berger, G.E.; Wellard, R.M.; Proffitt, T.M.; McConchie, M.; Berk, M.; McGorry, P.D.; Pantelis, C. Medial temporal lobe glutathione concentration in first episode psychosis: a 1HMRS investigation. Neurobiol. Dis., 2009, 33(3), 354-357.
34. Matsuzawa, D.; Obata, T.; Shirayama, Y.; Nonaka, H.; Kanazawa, Y.; Yoshitome, E.; Takanashi, J.; Matsuda, T.; Shimizu, E.; Ikehira, H.; Iyo, M.; Hashimoto, K. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One., 2008, 3(4), e1944.
35. Aytan, N.; Jung, T.; Tamturk, F.; Grune, T.; Kartal-Ozer, N. Oxidative stress related changes in the brain of hypercholesterolemic rabbits. Biofactors, 2008, 33(3), 225-236.
36. Tsai, G.; Goff, D.C.; Chang, R.W.; Flood, J.; Baer, L.; Coyle, J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry, 1998, 155(9), 1207-1213.
37. Songur, A.; Sarsilmaz, M.; Sogut, S.; Ozyurt, B.; Ozyurt, H.; Zararsiz, I.; Turkoglu, A. Hypotalamic superoxide dismutaze, xanthine oxidase, nitric oxide, and malondialdehyde in rats fed with fish w-3 fatty acids. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2004, 28, 693-698.
38. Nishioka, N.; Arnold, S. Evidence of oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am. J. Geriatr. Psychiatry, 2004, 12(2), 167-175.
39. Ponizovsky, A.M.; Barshtein, G.; Bergelson, L.D. Biochemical alterations of erythrocytes as an indicator of mental disorders: an overview. Harv. Rev. Psychiatry., 2003, 11(6), 317-332.
40. Olincy, A.; Young, D.A.; Freedman, R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol. Psychiatry, 1997, 42(1), 1-5.
41. D'Souza, B.; D'Souza, V. Oxidative injury and antioxidant vitamins E and C in Schizophrenia. Indian J. Clin. Biochem., 2003, 18(1), 87-90.
42. Dadheech, G.; Mishra, S.; Gautam, S. Oxidative stress, alphatocopherol, ascorbic acid and reduced glutathione status in schizophrenics. Indian J. Clin. Biochem., 2006, 21(2), 34-38.
43. Abdalla, D.S.; Monteiro, H.P.; Oliveira, J.A.; Bechara, E.J. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin. Chem., 1986, 32(5), 805-807.
44. Ben Othmen, L.; Mechri, A.; Fendri, C.; Bost, M.; Chazot, G.; Gaha, L.; Kerkeni, A. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(1), 155-159.
45. Kropp, S.; Kern, V.; Lange, K.; Degner, D.; Hajak, G.; Kornhuber, J.; Ruther, E.; Emrich, H.M.; Schneider, U.; Bleich, S. Oxidative stress during treatment with first-and second-generation antipsychotics. J. Neuropsychiatry. Clin. Neurosci., 2005, 17(2), 227-231.
46. Li, H.C.; Chen, Q.Z.; Ma, Y.; Zhou, J.F. Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J. Zhejiang Univ. Sci. B., 2006, 7(12), 981-986.
47. Pavlovic, D.; Tamburic, V.; Stojanovic, I. Oxidative stress as marker of possitive symptoms in schizophrenia. Facta Univ., 2002, 9(2), 157-161.
48. Sirota, P.; Gavrieli, R.; Wolach, B. Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity. Psychiatry Res., 2003, 121(2), 123-132.
49. Sivrioglu, E.Y.; Kirli, S.; Sipahioglu, D.; Gursoy, B.; Sarandol, E. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(7), 1493-1499.
50. Strassnig, M.; Singh Brar, J.; Ganguli, R. Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. Schizophr. Res., 2005, 76(2-3), 343-351.
51. Ustundag, B.; Atmaca, M.; Kirtas, O.; Selek, S.; Metin, K.; Tezcan, E. Total antioxidant response in patients with schizophrenia. Psychiatry Clin. Neurosci., 2006, 60(4), 458-464.
52. Yao, J.K.; Leonard, S.; Reddy, R. Altered glutathione redox state in schizophrenia. Dis. Markers, 2006, 22(1-2), 83-93.
53. Yao, J.K.; Reddy, R.; van Kammen, D.P. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res., 1998, 80(1), 29-39.
54. Zhang, X.; Zhou, D.; Cao, L.; Wu, G. The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl.), 2006, 188(1), 12-17.
55. Dakhale, G.; Khanzode, S.; Khanzode, S.; Saoji, A.; Khobragade, L.; Turankar, A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology, 2004, 49(4), 205-209.
56. Kuloglu, M.; Ustundag, B.; Atmaca, M.; Canatan, H.; Tezcan, A.E.; Cinkilinc, N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem. Funct., 2002, 20(2), 171-175.
57. Surapaneni, K. Status of lipid peroxidation, glutathione, ascorbic acid, vitamin E and antioxidant enzymes in schizophrenic patients. J. Clin. Diagn. Res., 2007, 1(2), 39-44.
58. Rukmini, M.; D'Souza, B.; D'Souza, V. Superoxide dismutase and catalase activities and their correlation with malondialdehyde in schizophrenic patients. Indian J. Clin. Biochem., 2004, 19(2), 114-118.
59. Altuntas, I.; Aksoy, H.; Coskun, I.; Caykoylu, A.; Akcay, F. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin. Chem. Lab. Med., 2000, 38(12), 1277-1281.
60. Halliwell, B.; Whiteman, M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br. J. Pharmacol., 2004, 142(2), 231-255.
61. Morera, A.L.; Intxausti, A.; Abreu-Gonzalez, P. Winter/summer seasonal changes in malondialdehyde formation as a source of variance in oxidative stress schizophrenia research. World J. Biol. Psychiatry, 2009, 10(4 Pt 2), 576-580.
62. Yao, J.K.; Reddy, R.; van Kammen, D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res., 2000, 97(2-3), 137-151.
63. Zhang, X.Y.; Tan, Y.L.; Zhou, D.F.; Cao, L.Y.; Wu, G.Y.; Haile, C.N.; Kosten, T.A.; Kosten, T.R. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J. Clin. Psychiatry, 2007, 68(5), 754-760.
64. Young, J.; McKinney, S.; Ross, B.; Wahle, K.; Boyle, S. Biomarkers of oxidative stress in schizophrenic and control subjects Prostaglandins Leukot. Essent. Fatty Acids, 2007, 76, 73-85.
65. Grignon, S.; Chianetta, J.M. Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(2), 365-369.
66. Uchida, K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid. Res., 2003, 42(4), 318-343.
67. Dietrich-Muszalska, A.; Olas, B. Isoprostenes as indicators of oxidative stress in schizophrenia. World J. Biol. Psychiatry, 2007, 1-7.
68. Buss, H.; Chan, T.P.; Sluis, K.B.; Domigan, N.M.; Winterbourn, C.C. Protein carbonyl measurement by a sensitive ELISA method. Free Radic. Biol. Med., 1997, 23(3), 361-366.
69. Dietrich-Muszalska, A.; Olas, B. Modifications of blood platelet proteins of patients with schizophrenia. Platelets, 2009, 20(2), 90-96.
70. Dietrich-Muszalska, A.; Olas, B.; Glowacki, R.; Bald, E. Oxidative/ nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology, 2009, 59(1), 1-7.
71. Akanji, A.O.; Ohaeri, J.U.; Al-Shammri, S.A.; Fatania, H.R. Associations of blood homocysteine concentrations in Arab schizophrenic patients. Clin. Biochem., 2007, 40(13-14), 1026-1031.
72. Mattson, M.P.; Shea, T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci., 2003, 26(3), 137-146.
73. Halliwell, B. Why and how should we measure oxidative DNA damage in nutritional studies? How far have we come? Am. J. Clin. Nutr., 2000, (72), 1082-1087.
74. Psimadas, D.; Messini-Nikolaki, N.; Zafiropoulou, M.; Fortos, A.; Tsilimigaki, S.; Piperakis, S.M. DNA damage and repair efficiency in lymphocytes from schizophrenic patients. Cancer Lett., 2004, 204(1), 33-40.
75. Virit, O.; Altindag, A.; Yumru, M.; Dalkilic, A.; Savas, H.A.; Selek, S.; Erel, O.; Herken, H. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology, 2009, 60(2), 87-93.
76. Pazvantoglu, O.; Selek, S.; Okay, I.T.; Sengul, C.; Karabekiroglu, K.; Dilbaz, N.; Erel, O. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin. Neurosci., 2009, 63(5), 693-700.
77. Yilmaz, N.; Herken, H.; Cicek, H.K.; Celik, A.; Yurekli, M.; Akyol, O. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med. Princ. Pract., 2007, 16(2), 137-141.
78. Dietrich-Muszalska, A.; Olas, B. The changes of aggregability of blood platelets in schizophrenia. World J. Biol. Psychiatry, 2009, 10(2), 171-176.
79. Yao, J.K.; Thomas, E.A.; Reddy, R.D.; Keshavan, M.S. Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia. Schizophr. Res., 2005, 72(2-3), 259-266.
80. Ozcankaya, D.; Eren, I. Activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) and levels of malondialdehyde (MDA) reduced gluthatione (GSH) in schizophrenia patients with negative or positive symptoms. Biomed. Res., 2001, 12(3), 225-230.
81. Sarandol, A.; Kirli, S.; Akkaya, C.; Altin, A.; Demirci, M.; Sarandol, E. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(6), 1164-1169.
82. Evans, D.; Parikh, V.; Khan, M.; CCoussons; Buckley, P.; Mahadik, S. Red blood cell membrane essential fatty acid metabolism in early psychotic. Prostaglandins Leukot. Essent. Fatty Acids, 2003, 69, 393-399.
83. Yamada, K.; Kanba, S.; Anamizu, S. Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia. Psychol. Med., 1997, 27(5), 1223-1225.
84. Medina-Hernandez, V.; Ramos-Loyo, J.; Luquin, S. Increased lipid peroxidation and neuron specific enolase in treatment refractory schizophrenics. J. Psychiatr. Res., 2007, 41(8), 652-658.
85. Gama, C.S.; Salvador, M.; Andreazza, A.C.; Lobato, M.I.; Berk, M.; Kapczinski, F.; Belmonte-De-Abreu, P.S. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci. Lett., 2008, 433(3), 270-273.
86. Smythies, J.R. Oxidative reactions and schizophrenia: a reviewdiscussion. Schizophr. Res., 1997, 24(3), 357-364.
87. Masserano, J.M.; Baker, I.; Venable, D.; Gong, L.; Zullo, S.J.; Merril, C.R.; Wyatt, R.J. Dopamine induces cell death, lipid peroxidation and DNA base damage in a catecholaminergic cell line derived from the central nervous system. Neurotox. Res., 2000, 1(3), 171-179.
88. Ben-Shachar, D.; Zuk, R.; Glinka, Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem., 1995, 64(2), 718-723.
89. Blum, D.; Torch, S.; Lambeng, N.; Nissou, M.; Benabid, A.L.; Sadoul, R.; Verna, J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol., 2001, 65(2), 135-172.
90. Hermida-Ameijeiras, A.; Mendez-Alvarez, E.; Sanchez-Iglesias, S.; Sanmartin-Suarez, C.; Soto-Otero, R. Autoxidation and MAOmediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem. Int., 2004, 45(1), 103-116.
91. Kopin, I.J. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol. Rev., 1985, 37(4), 333-364.
92. Mazzio, E.A.; Soliman, K.F. Glioma cell antioxidant capacity relative to reactive oxygen species produced by dopamine. J. Appl. Toxicol., 2004, 24(2), 99-106.
93. Linert, W.; Jameson, G.N. Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's Disease. J. Inorg. Biochem., 2000, 79(1-4), 319-326.
94. Taneli, F.; Pirildar, S.; Akdeniz, F.; Uyanik, B.S.; Ari, Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch. Med. Res., 2004, 35(5), 401-405.
95. Bernstein, H.G.; Bogerts, B.; Keilhoff, G. The many faces of nitric oxide in schizophrenia. A review. Schizophr. Res., 2005, 78(1), 69-86.
96. Herken, H.; Uz, E.; Ozyurt, H.; Akyol, O. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr. Res., 2001, 52(3), 289-290.
97. Reif, A.; Herterich, S.; Strobel, A.; Ehlis, A.C.; Saur, D.; Jacob, C.P.; Wienker, T.; Topner, T.; Fritzen, S.; Walter, U.; Schmitt, A.; Fallgatter, A.J.; Lesch, K.P. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol. Psychiatry, 2006, 11(3), 286-300.
98. Srivastava, N.; Barthwal, M.K.; Dalal, P.K.; Agarwal, A.K.; Nag, D.; Srimal, R.C.; Seth, P.K.; Dikshit, M. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl), 2001, 158(2), 140-145.
99. Sipos, I.; Tretter, L.; Adam-Vizi, V. Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals. J. Neurochem., 2003, 84(1), 112-118.
100. Prabakaran, S.; Swatton, J.E.; Ryan, M.M.; Huffaker, S.J.; Huang, J.T.; Griffin, J.L.; Wayland, M.; Freeman, T.; Dudbridge, F.; Lilley, K.S.; Karp, N.A.; Hester, S.; Tkachev, D.; Mimmack, M.L.; Yolken, R.H.; Webster, M.J.; Torrey, E.F.; Bahn, S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry, 2004, 9(7), 684-697, 643.
101. Frey, B.N.; Valvassori, S.S.; Gomes, K.M.; Martins, M.R.; Dal-Pizzol, F.; Kapczinski, F.; Quevedo, J. Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res., 2006, 1097, 224-229.
102. Rezin, G.T.; Amboni, G.; Zugno, A.I.; Quevedo, J.; Streck, E.L. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res., 2009, 34(6), 1021-1029.
103. Casademont, J.; Garrabou, G.; Miro, O.; Lopez, S.; Pons, A.; Bernardo, M.; Cardellach, F. Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. J. Clin. Psychopharmacol., 2007, 27(3), 284-288.
104. Stober, G.; Ben-Shachar, D.; Cardon, M.; Falkai, P.; Fonteh, A.N.; Gawlik, M.; Glenthoj, B.Y.; Grunblatt, E.; Jablensky, A.; Kim, Y.K.; Kornhuber, J.; McNeil, T.F.; Muller, N.; Oranje, B.; Saito, T.; Saoud, M.; Schmitt, A.; Schwartz, M.; Thome, J.; Uzbekov, M.; Durany, N.; Riederer, P. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J. Biol. Psychiatry, 2009, 10(2), 127-155.
105. Virgos, C.; Martorell, L.; Valero, J.; Figuera, L.; Civeira, F.; Joven, J.; Labad, A.; Vilella, E. Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr. Res., 2001, 49(1-2), 65-71.
106. Thelma, B.K.; Tiwari, A.K.; Deshpande, S.N.; Lerer, B.; Nimgaonkar, V.L. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes. Schizophr. Res., 2007, 92(1-3), 278-279.
107. Gysin, R.; Kraftsik, R.; Sandell, J.; Bovet, P.; Chappuis, C.; Conus, P.; Deppen, P.; Preisig, M.; Ruiz, V.; Steullet, P.; Tosic, M.; Werge, T.; Cuenod, M.; Do, K.Q. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc. Natl. Acad. Sci. USA, 2007, 104(42), 16621-16626.
108. Shinkai, T.; Muller, D.J.; De Luca, V.; Shaikh, S.; Matsumoto, C.; Hwang, R.; King, N.; Trakalo, J.; Potapova, N.; Zai, G.; Hori, H.; Ohmori, O.; Meltzer, H.Y.; Nakamura, J.; Kennedy, J.L. Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. Psychiatry Res., 2006, 141(2), 123-128.
109. Hori, H.; Ohmori, O.; Shinkai, T.; Kojima, H.; Okano, C.; Suzuki, T.; Nakamura, J. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology, 2000, 23(2), 170-177.
110. Sagara, Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem., 1998, 71(3), 1002-1012.
111. Iwahashi, K.; Anemo, K.; Nakamura, K.; Fukunishi, I.; Igarashi, K. Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with drug-induced parkinsonism. Neuropsychobiology, 2001, 44(3), 126-128.
112. Reinke, A.; Martins, M.R.; Lima, M.S.; Moreira, J.C.; Dal-Pizzol, F.; Quevedo, J. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci. Lett., 2004, 372(1-2), 157-160.
113. Wei, Z.; Bai, O.; Richardson, J.S.; Mousseau, D.D.; Li, X.M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosci. Res., 2003, 73(3), 364-368.
114. Pillai, A.; Parikh, V.; Terry, A.V., Jr.; Mahadik, S.P. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res., 2007, 41(5), 372-386.
115. Fehsel, K.; Loeffler, S.; Krieger, K.; Henning, U.; Agelink, M.; Kolb-Bachofen, V.; Klimke, A. Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J. Clin. Psychopharmacol., 2005, 25(5), 419-426.
116. Soares, K.; McGrath, J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev., 2001, 4. DOI: 10.1002/ 14651858.CD000209.
117. Nicolaus, M.; Hildegard, S.; Volker, A.; Erfurth, A. Severe tardive dyskinesia in affective disorders:treatment with vitamin E and C. Neuropsychobiology, 2002, 46(1), 28-30.
118. Berk, M.; Copolov, D.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Judd, F.; Katz, F.; Katz, P.; Ording-Jespersen, S.; Little, J.; Conus, P.; Cuenod, M.; Do, K.Q.; Bush, A.I. N-acetyl cysteine as a glutathione precursor for schizophreniaa double-blind, randomized, placebo-controlled trial. Biol. Psychiatry, 2008, 64(5), 361-368.
119. Bulut, M.; Savas, H.A.; Altindag, A.; Virit, O.; Dalkilic, A. Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. World J. Biol. Psychiatry, 2009, 10(4 Pt 2), 626-628.
120. Lavoie, S.; Murray, M.M.; Deppen, P.; Knyazeva, M.G.; Berk, M.; Boulat, O.; Bovet, P.; Bush, A.I.; Conus, P.; Copolov, D.; Fornari, E.; Meuli, R.; Solida, A.; Vianin, P.; Cuenod, M.; Buclin, T.; Do, K.Q. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology, 2008, 33(9), 2187-2199.
121. Dodd, S.; Dean, O.; Copolov, D.L.; Malhi, G.S.; Berk, M. Nacetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin. Biol. Ther., 2008, 8(12), 1955-1962.
122. Bishnoi, M.; Chopra, K.; Kulkarni, S. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Fundam. Clin. Pharmacol., 2007, 21, 521-529.
123. Singh, V.; Singh, S.P.; Chan, K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int. J. Neuropsychopharmacol., 2010, 13(2), 257-271.
124. Zhang, X.; Zhou, D.; Su, J.; Zhang, P. The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J. Clin. Psychopharmacol., 2001, 21, 85-88.
125. Atmaca, M.; Tezcan, E.; Kugolu, M.; Ustundang, B.; Kirtas, O. The effect of extract of Ginkgo biloba addition to Olanzapine therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin. Neurosci., 2005, 59(6), 652-656.
126. Rathbone, J.; Zhang, L.; Zhang, M.; Xia, J.; Liu, X.; Yang, Y. Chinese herbal medicine for schizophrenia. Cochrane Database Syst. Rev., 2005, (4), CD003444.
127. Shamir, E.; Barak, Y.; Shalman, I.; Laudon, M.; Zisapel, N.; Tarrasch, R.; Elizur, A.; Weizman, R. Melatonin treatment for tardive dyskinesia: a double-blind, placebo controlled, crossover study. Arch. Gen. Psychiatry, 2001, 58(11), 1049-1052.
128. Ortiz, G.G.; Benitez-King, G.A.; Rosales-Corral, S.A.; Pacheco-Moises, F.P.; Velazquez-Brizuela, I.E. Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders. Curr. Neuropharmacol., 2008, 6(3), 203-214.
129. Maldonado, M.D.; Reiter, R.J.; Perez-San-Gregorio, M.A. Melatonin as a potential therapeutic agent in psychiatric illness. Hum. Psychopharmacol., 2009, 24(5), 391-400.
130. Young, J.; Wahle, K.; Boyle, S. Cytoprotective effects of phenolic antioxidants and essential fatty acids in human blodd monocyte and neuroblastoma cell lines: Surrogates for neurological damage in vivo. Prostaglandins Leukot. Essent. Fatty Acids, 2007, 78(1), 45-59.
131. Ozyurt, B.; Ozyrut, H.; Akpolat, N.; Erdogan, H.; Sarsilmaz, M. Oxidative stress in prefrontal cortex of ret exposed to MK-801 and protective effects of CAPE. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 832-838.
132. Dietrich-Muszalska, A.; Olas, B. Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro. World J. Biol. Psychiatry, 2009, 1-6.
133. Rao, A.; Rao, L. Lycopene and human health. Curr. Top. Nutraceutical Res., 2004, 2(3), 127-136.
134. Rao, A.; Balachandran, B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr. Neurosci., 2002, 5(5), 291-309.
135. Mazza, M.; Pomponi, M.; Janiri, L.; Bria, P.; Mazza, S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(1), 12-26.
136. Sarsilmaz, M.; Songur, A.; Ozyurt, H.; Kus, I.; Ozen, A.; Ozyurt, B.; Sogut, S.; Akyol, O. Potential role of dietary _-3 essential fatty acids on some oxidant/antioxidant parameters in rats' corpus striatum. Prostaglandins Leukot. Essent. Fatty Acids, 2003, 69, 253-259.
137. Fenton, W.S.; Hibbeln, J.; Knable, M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol. Psychiatry, 2000, 47(1), 8-21.
138. Adler, L.A.; Peselow, E.; Rotrosen, J.; Duncan, E.; Lee, M.; Rosenthal, M.; Angrist, B. Vitamin E treatment of tardive dyskinesia. Am. J. Psychiatry, 1993, 150(9), 1405-1407.
139. Adler, L.A.; Rotrosen, J.; Edson, R.; Lavori, P.; Lohr, J.; Hitzemann, R.; Raisch, D.; Caligiuri, M.; Tracy, K. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch. Gen. Psychiatry, 1999, 56(9), 836-841.
140. Dabiri, L.M.; Pasta, D.; Darby, J.K.; Mosbacher, D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am. J. Psychiatry, 1994, 151(6), 925-926.
141. Elkashef, A.M.; Ruskin, P.E.; Bacher, N.; Barrett, D. Vitamin E in the treatment of tardive dyskinesia. Am. J. Psychiatry, 1990, 147(4), 505-506.
142. Lam, L.C.; Chiu, H.F.; Hung, S.F. Vitamin E in the treatment of tardive dyskinesia: a replication study. J. Nerv. Ment. Dis., 1994, 182(2), 113-114.
143. Lohr, J.B.; Caligiuri, M.P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J. Clin. Psychiatry, 1996, 57(4), 167-173.
144. Sajjad, S.H. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses. Int. Clin. Psychopharmacol., 1998, 13(4), 147-155.
145. Rosenheck, R.A. Pharmacotherapy of first-episode schizophrenia. Lancet, 2008, 371(9618), 1048-1049.
146. Dakhale, G.N.; Khanzode, S.D.; Khanzode, S.S.; Saoji, A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl), 2005, 182(4), 494-498.
147. Joy, S.; Mumby-Croft, R.; Joy, L. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst. Rev., 2006, (2). DOI: 10.1002/14651858.CD001257.pub2.
148. Emsley, R.; Niehaus, D.J.; Koen, L.; Oosthuizen, P.P.; Turner, H.J.; Carey, P.; van Rensburg, S.J.; Maritz, J.S.; Murck, H. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr. Res., 2006, 84(1), 112-120.
149. Fenton, W.S.; Dickerson, F.; Boronow, J.; Hibbeln, J.R.; Knable, M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry, 2001, 158(12), 2071-2074.
150. Peet, M.; Brind, J.; Ramchand, C.N.; Shah, S.; Vankar, G.K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res., 2001, 49(3), 243-251.
151. Peet, M.; Horrobin, D.F. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res., 2002, 36(1), 7-18.
152. Emsley, R.; Myburgh, C.; Oosthuizen, P.; van Rensburg, S.J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry, 2002, 159(9), 1596-1598.
153. Arvindakshan, M.; Ghate, M.; Ranjekar, P.K.; Evans, D.R.; Mahadik, S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr. Res., 2003, 62(3), 195-204.